Literature DB >> 29717820

Mobile Intensive Care Unit: A case management team dedicated to early psychosis in France.

Laurent Lecardeur1,2,3, Sophie Meunier-Cussac2, Sonia Dollfus1,2,3.   

Abstract

AIM: To present the activities of a Mobile Intensive Care Unit in France.
METHODS: We summarize participant recruitment as well as the diagnostic procedures and therapeutic interventions offered to individuals with an at-risk mental state or first-episode psychosis (FEP).
RESULTS: Since its inception in 2010, 266 individuals from 16 to 30 years old living in an area of 120 000 citizens have been recruited by the Mobile Intensive Care Unit. Patients are evaluated by clinical and neuropsychological assessments, and therapeutic interventions include medication, individual case management and both individual and group cognitive behavioural therapy. Diagnostic assessments are also provided for the patients outside of our geographic area.
CONCLUSIONS: The Mobile Intensive Care Unit is a functional unit enabling young adults with a high-risk mental state or FEP to receive high standard of care and mobile management over 2 years, aimed at diminishing the risk of transition to chronic disease and decreasing functional impairment.
© 2018 John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  case management; early intervention; first-episode psychosis; treatment; ultra-high risk

Mesh:

Year:  2018        PMID: 29717820     DOI: 10.1111/eip.12674

Source DB:  PubMed          Journal:  Early Interv Psychiatry        ISSN: 1751-7885            Impact factor:   2.732


  1 in total

1.  Lived experiences: a focus group pilot study within the MentALLY project of mental healthcare among European users.

Authors:  Malin Axelsson; Viktor Schønning; Claudi Bockting; Ann Buysse; Mattias Desmet; Alexis Dewaele; Theodoros Giovazolias; Dewi Hannon; Konstantinos Kafetsios; Reitske Meganck; Spyridoula Ntani; Kris Rutten; Sofia Triliva; Laura Van Beveren; Joke Vandamme; Simon Øverland; Gunnel Hensing
Journal:  BMC Health Serv Res       Date:  2020-07-01       Impact factor: 2.655

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.